In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Kyeong Beom JoSurgical and Interventional Sciences, Department of Surgery, McGill University, Montreal, Quebec, Canada.ORCID 0000-0001-6254-2030 Mohammed M AlruwailiDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0003-2811-4387 Da-Eun KimDepartment of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul, Korea.ORCID 0009-0007-4887-0063 Yongjun KohGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
Hyeyeon KimCancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-0489-7682 Ji-Sun KimCancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-4863-9773 Saba SaneSurgical and Interventional Sciences, Department of Surgery, McGill University, Montreal, Quebec, Canada.ORCID 0009-0008-3832-842X Yanqi GuoDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Jacob P WrightDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Maricris N NaranjoDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Atina G CoteDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-0340-9325 Frederick P RothDepartment of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, USA.ORCID 0000-0002-6628-649X David E HillCenter for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0001-5192-0921 Hunsang LeeDepartment of Life Sciences, School of Life Sciences and Biotechnology, Korea University, Seoul, Korea.
Kenneth A MatreyekDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0001-9149-551X Kyle K-H FarhIllumina Artificial Intelligence Laboratory, Illumina Inc., San Diego, California, USA.ORCID 0000-0001-6947-8537 Jong-Eun ParkGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.ORCID 0000-0002-1687-2423 HyunKyung KimDepartment of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul, Korea.
Andrei V BakinDepartment of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0002-7728-1969 Dae-Kyum KimSurgical and Interventional Sciences, Department of Surgery, McGill University, Montreal, Quebec, Canada.ORCID 0000-0003-4568-8278 Funding
Novel synthetic lethality strategy for TP53 mutant colorectal cancerR37CA282430 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christos Fountzilas · 2023 to 2026
$2.1MA Novel Treatment Strategy for Metastatic Breast CancerR21CA259719 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BAKIN, ANDREI V. · 2022 to 2023
$429kNCI NIH HHS R21 CA259719NCI NIH HHS R37 CA282430
6 · The paper itselfAbstract
Cancer drug resistance remains a major barrier to durable treatment success, often leading to relapse despite advances in precision oncology. While combination therapies are being increasingly investigated, such as chemotherapy with small molecule inhibitors, predicting drug response and identifying rational drug combinations based on resistance mechanisms remain major challenges. Therefore, a proteome-wide, single-gene overexpression screening platform is essential for guiding rational therapy selection. Here, we present
Identifiers
PMID40950237
PMCPMC12424776
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390